Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyNicole M. Kuderer, Kerry L. Reynolds, Dimitrios Farmakiotis et al.|The Lancet|2020Cited by 1.8k
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancerLisa Derosa, Benjamin Besse, Bertrand Routy et al.|Nature Medicine|2022Cited by 637
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trialBertrand Routy, Saman Maleki Vareki, John Lenehan et al.|Nature Medicine|2023Cited by 446
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer ConsortiumPetros Grivas, Shuchi Gulati, Ali Raza Khaki et al.|Annals of Oncology|2021Cited by 326
A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut MicrobiotaMeriem Messaoudene, Bertrand Routy, Reilly Pidgeon et al.|Cancer Discovery|2022Cited by 225